Ascendis Pharma A (ASND) Income from Continuing Operations (2014 - 2026)

Ascendis Pharma A has disclosed Income from Continuing Operations across 13 years of filings, most recently posting 736795896.67 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 736795896.67, up 857.21% year-over-year; the trailing twelve-month figure through Mar 2026 was 615578672.64 (up 270.95% YoY), and the FY2025 annual result was 201331802.26, up 50.17% from the prior year.
• Income from Continuing Operations came in at 736795896.67 for Q1 2026 at Ascendis Pharma A, up from 23103935.68 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 736795896.67 in Q1 2026 to a low of 200706122.44 in Q4 2022.
• The 5-year median for Income from Continuing Operations is 106700810.43 (2024), against an average of 58462322.76.
• Across the five-year window, Income from Continuing Operations plunged 85.25% in 2022 and soared 857.21% in 2026, its largest moves.
• Ascendis Pharma A's Income from Continuing Operations stood at 200706122.44 in 2022, then jumped by 59.64% to 81013971.39 in 2023, then soared by 52.12% to 38788944.43 in 2024, then soared by 40.44% to 23103935.68 in 2025, then soared by 3289.05% to 736795896.67 in 2026.
• The last three Income from Continuing Operations figures came in at 736795896.67 (Q1 2026), 23103935.68 (Q4 2025), and 62842556.44 (Q3 2025), per Business Quant data.